Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China. BACKGROUND: The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) edoxaban for the treatment of patients with non-valv...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, X Y, Du, J, Hiroshi, H, Yang, Y, Wu, M X, Qu, W C, Han, X B, Wang, Z F, Jin, J, Zhang, P, Zhang, Z, Liu, M Q, Unverdorben, M, Chen, C, Ma, C S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
10.5.1 - Oral Anticoagulation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207620/
http://dx.doi.org/10.1093/europace/euad122.207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207620/
http://dx.doi.org/10.1093/europace/euad122.207

Ejemplares similares